TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01626872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 3mg
Description: In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 6mg
Description: In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 9mg
Description: In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone 4mg
Description: In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4. In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
Study: NCT02998268

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: OTHER
Intervention: Taxol
Description: Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.
Study: NCT02451709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activated Smartinhaler or Smartturbo
Description: Medication reminder alarms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback of adherence data
Description: Review of adherence data with action planning

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deactivated Smartinhaler or Smartturbo
Description: Alarms deactivated and no feedback
Study: NCT00574522

Intervention type: RADIATION
Group type: OTHER
Intervention: Far infrared
Description: Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.
Study: NCT01033799

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non fermented dairy product (control)
Study: NCT03881527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement using a nitinol blade
Description: A circular nitinol blade will be inserted by to cut the aortic valve leaflets during conventional aortic valve replacement procedure

Intervention type: PROCEDURE
Group type: OTHER
Intervention: aortic valve replacement
Description: Aortic valve replacement in a standard fashion
Study: NCT02598583

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALXN1210
Description: Participants were administered ravulizumab as an IV infusion every 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALXN1210
Description: Participants were administered ravulizumab as an IV infusion every 4 weeks.
Study: NCT01578876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiac shock wave therapy(CSWT)
Description: CSWT was performed with the MODULITH SLC SW therapy device (Storz Medical, Switzerland).Shock waves were triggered by the R-wave of the ECG when the instrument was activated. The shock wave energy was increased from an initial low level up 0.09 mJ/mm2 if the patient experienced no discomfort such as chest pain. Point-to-point combination treatment for the ischemic areas with 200 pulses delivered to each point was given.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardiac shock wave therapy(CSWT)
Description: CSWT was performed with the MODULITH SLC SW therapy device (Storz Medical, Switzerland).Shock waves were triggered by the R-wave of the ECG when the instrument was activated. The shock wave energy was increased from an initial low level up 0.09 mJ/mm2 if the patient experienced no discomfort such as chest pain. Point-to-point combination treatment for the ischemic areas with 200 pulses delivered to each point was given.
Study: NCT03172416

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: This study started as a prospective, single arm phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC using oxaliplatin in patients with peritoneal carcinomatosis.

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin & Nivolumab
Description: PIPAC oxaliplatin 90mg/m2 has been well tolerated in our Cohort 1 study. Hence, we added a second cohort (Cohort 2) which combines PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks to evaluate the safety and tolerability of combination therapy.
Study: NCT01915069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Study: NCT00946283

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: Culturelle DS (Lactobacillus GG) will be administered one capsule (10 billion live lactobacillus GG) daily with water
Study: NCT00728403

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American Ginseng (Panax quinquefolius L.) and Korean Red Ginseng (steamed Panax C.A. Meyer)
Description: 1.5 grams American Ginseng and 1.5 grams Korean Red Ginseng are to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American Ginseng (Panax quinquefolius L.)
Description: 3 grams of American Ginseng is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Bran
Description: 3 grams of Wheat Bran is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
Study: NCT03810105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300mg twice daily (600mg total daily dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg IV monthly
Study: NCT01850758

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regenexx SD
Description: stem cell treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: exercise therapy control
Study: NCT01607684

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Marker Imaging (MMI) with Magma 3D system
Description: Magnetic Marker Imaging (MMI). It comprises of a high-resolution three-dimensional detector system, that detects passively and continuously the magnetic field of a magnetic marker capsule (1g, 6x12mm), which is taken orally by the subject. Changes in frequency, intensity and duration of oscillating marker movements allow us to delineate migrating gastric motor complexes. The Magnetic Marker Imaging takes up to 4 h in which the patient lies in a bed. Short interruptions (e.g. to visit the restroom) during this 4 h period are possible.

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Marker Imaging (MMI) with Magma 3D system
Description: Magnetic Marker Imaging (MMI). It comprises of a high-resolution three-dimensional detector system, that detects passively and continuously the magnetic field of a magnetic marker capsule (1g, 6x12mm), which is taken orally by the subject. Changes in frequency, intensity and duration of oscillating marker movements allow us to delineate migrating gastric motor complexes. The Magnetic Marker Imaging takes up to 4 h in which the patient lies in a bed. Short interruptions (e.g. to visit the restroom) during this 4 h period are possible.
Study: NCT04628325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Intravenous Furosemide Plus Small Hypertonic Saline Solutions (HSS)
Study: NCT00936780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infinnium-Core™ Paclitaxel eluting Coronary Stent
Description: Infinnium-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Drug concentration is 1.36 µg/mm2.
Study: NCT02668393

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel

Intervention type: DRUG
Group type: OTHER
Intervention: Nintedanib
Description: Low Dose

Intervention type: DRUG
Group type: OTHER
Intervention: Nintedanib
Description: Medium dose

Intervention type: DRUG
Group type: OTHER
Intervention: Nintedanib
Description: High dose

Intervention type: DRUG
Group type: OTHER
Intervention: Nintedanib
Description: Continuous high dose
Study: NCT04618107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide awake surgery
Description: Wide awake local anaesthesia was used to perform tendon repair surgeries.Local anaesthetic injections given using 27 gauze needle in subcutaneous tissue plane.Tendon repair performed using modified Kessler repair.Outcome of surgery assesed at sixth postoprative week.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: Tendon repair performed under general anaesthesia using modified Kessler repair.Outcomes of surgery assesed at sixth post operative week
Study: NCT01933685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: 1 mL per injection (300 ug dose/antigen for a total of 600 ug/dose administered)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIDSVAX B/E Placebo
Description: 1 mL per injection
Study: NCT03207061

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3D Ultrasound
Description: A 3D ultrasound will be performed for all patients presenting to the clinic for suspected endometrial cancer (in addition to routine standard of care)
Study: NCT03695367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vial access device
Description: Device for withdrawal of drug product.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vial access device
Description: Device for withdrawal of drug product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen, 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen, 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen, 1 g.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen, 1 g.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Intraoperative IV ketorolac.
Study: NCT00644982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: Flexibly-titrated 50 mg tablets, 50-150 mg/day and venlafaxine placebo orally for 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine XR
Description: Flexibly-titrated 75 mg capsules, 75-225mg/day and sertraline placebo orally for 10 weeks.
Study: NCT01809743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson central -central
Description: To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson peripheral - peripheral
Description: To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson central - peripheral
Description: To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson peripheral - central
Description: To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
Study: NCT03453138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Protector
Description: LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracheal Intubation
Description: tracheal intubation will be perform after standart anaesthetic induction and heamodynamic variables including blood pressure heart rate and possible complications will be observed
Study: NCT04695808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: Yoga practice will be done two days a week for 10 weeks.
Study: NCT02344524

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal drainage
Description: Small bore chest drains are inserted by modified Seldinger's technique. Large bore chest drains are inserted by blunt dissection technique.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intercostal drainage
Description: Small bore chest drains are inserted by modified Seldinger's technique. Large bore chest drains are inserted by blunt dissection technique.
Study: NCT03519711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC923
Description: PTC923 will be administered per dose and schedule specified in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC923
Description: PTC923 will be administered per dose and schedule specified in arm description.
Study: NCT00986037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-308
Description: Single IV doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-308
Description: Single IV doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-308
Description: Multiple SC doses x 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple SC doses x 3
Study: NCT04469764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study: NCT03869697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB-313
Description: 5 mg or 20 mg lyophilized powder in a single-use glass vial
Study: NCT01638871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainCOACH
Description: The 8-week Internet-based pain coping skills intervention program includes 8 sessions. Each session takes 30-45 minutes to complete and includes text, illustrations, photos, animations, audio narration, interactivity, and delivery of personalized feedback. Users will be expected to complete 1 session per week.
Study: NCT00176267

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50 cGy on days 1, 2, 8, 15, 22, 23, 29 \& 36 of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 75 mg/m2 intravenously over one hour on Days 1, 8, 15, 22, 29 and 36

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC of 6 on Days 1 \& 22
Study: NCT04664127

Intervention type: DRUG
Intervention: Kagocel+Valacyclovir
Description: Group 1-patients with simple severe herpes (HSV-infection orolabial and / or genital localization) treatment \[Valacyclovir + Kagocel ° \] (n= 25).~Treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (the rate of suppressive therapy). \* Kagocel®, 24 mg orally (2 tablets of 12 mg): 3 times per day, 5 days continuously.~\* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months

Intervention type: DRUG
Intervention: Valacyclovir
Description: Group 2 -patients with simple severe herpes (HSV-infection orolabial and/or genital localization) receiving treatment \[Valacyclovir\] (n= 20).~Scheme of treatment: Valacyclovir, 1000 mg orally (2 tablets of 500 mg): 1 time per day for at least 4 months continuously (a course of suppressive therapy)\*.~\* - During the study the minimum duration of Valacyclovir suppressive therapy in instruction for medical use that drag was changed from 4 (what was using in our reserch) to 6 months, and the optimal duration of continuous antiviral therapy with PG was changed from 6 to 12 months.
Study: NCT00607373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Description: 200 mg mipomersen administered once a week for 26 weeks as a 1 mL subcutaneous injection. Subjects weighing less than 50 kg received a lower dose of 160 mg (0.8mL) mipomersen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL subcutaneous injection once a week for 26 weeks. Subjects weighing less than 50 kg received 0.8 mL subcutaneous injection.
Study: NCT03722004

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mOPV1
Description: Monovalent oral poliovirus vaccine type 1 is a type-specific, live, attenuated oral poliovirus vaccine that protects against poliovirus type 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mOPV1
Description: Monovalent oral poliovirus vaccine type 1 is a type-specific, live, attenuated oral poliovirus vaccine that protects against poliovirus type 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mOPV1
Description: Monovalent oral poliovirus vaccine type 1 is a type-specific, live, attenuated oral poliovirus vaccine that protects against poliovirus type 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV
Description: Bivalent oral poliovirus vaccine is a live, attenuated oral poliovirus vaccine that protects against poliovirus types 1 and 3.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fIPV
Description: Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal injection in lieu of the full 0.5mL dose that is given intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fIPV
Description: Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal injection in lieu of the full 0.5mL dose that is given intramuscularly.
Study: NCT01809119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial nephrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial nephrectomy